Precision, complexity and stigma in advanced prostate cancer terminology: It is time to move away from 'castration-resistant' prostate cancer

ANZUP Consumer Advisory Panel

Research output: Contribution to journalEditorialpeer-review

4 Scopus citations
Original languageEnglish (US)
Pages (from-to)1692-1694
Number of pages3
JournalAnnals of Oncology
Issue number8
StatePublished - Aug 1 2017

Bibliographical note

Funding Information:
CP: advisory boards (compensated): Novartis. Honoraria: Janssen, Pfizer, Sanofi, Novartis, Astellas. Travel support: Pfizer, Sanofi, Amgen. AO: advisory boards (compensated, institutional): Bayer, Astellas, Janssen, Sanofi, Pfizer. Travel support: Bayer, Astellas, Janssen, Sanofi. Research support (institutional): Janssen, Teva. FS: advisory boards, honoraria and research: Amgen, Astellas. Bayer, Janssen, Sanofi, Takeda. SG: advisory boards: AAA, Astellas, Bayer, Curevac, Dendreon, Janssen Cilag, Janssen Diagnostics, Millennium, Novartis, Orion Pharma, Pfizer, Sanofi Aventis. Advisory Boards (uncompensated): ProteoMediX, ESSA Pharmaceuticals Corp. Speakers Bureau (without personal honorarium): Amgen, Astellas, Bayer, Janssen Cilag, Novartis, Sanofi Aventis. IDD is supported by an NHMRC Practitioner Fellowship (APP1102604).

Cite this